 |
| |
| For Immediate Release |
| |
Prodesse's
Hexaplex® Selected for Use in Phase 3 Clinical Trial
WAUKESHA, WI (June 20, 2005) - Prodesse announced today that it recently signed
an agreement with a global pharmaceutical firm for Prodesse to perform its Hexaplex
assay as part of an FDA phase 3 clinical trial. Hexaplex will be used to determine
efficacy of the preventative treatment. According to
Karen Harrington, PhD, Clinical Laboratory Manager, "The selection of Prodesse’s
Hexaplex for a primary clinical endpoint study is further testimony to the performance
and quality of our Hexaplex assay. We have had a number of other large organizations
use our products for their precise pathogen detection requirements, but this
is the first time we have had to pass the rigorous audits associated with a phase
3 study." |
|
About Prodesse
Prodesse is a biotechnology company focused on developing analyte specific reagents
that can be used by CLIA certified laboratories to develop assays for detecting
infectious disease pathogens. The Company's reagents incorporate proprietary
technology that allows for the detection of multiple pathogens. Prodesse
currently offers nine different multiplex products covering 33 different
organisms. The company’s products can be used on a variety of detection
platforms. The Company sells its reagents to laboratories throughout the
US and the world, and also operates a CLIA certified laboratory for testing
services in the Midwest area. For more information about Prodesse and its
products, call 888-589-6974 or go to www.prodesse.com.
|
| |
| |
Press Contact:
Andy Shrago, Chief Marketing Officer
Prodesse, Inc.
Phone: (262) 446-0700
ashrago@prodesse.com |
| |
|
| |
|
